J&J, Legend cell therapy approved by FDA for multiple myeloma
Bio Pharma Dive
FEBRUARY 28, 2022
The CAR-T treatment is the second to be approved in the U.S. for the blood cancer, following Bristol Myers Squibb and 2Seventy bio's Abecma.
Sat.Feb 26, 2022 - Fri.Mar 04, 2022
363 
How should DTC evolve?
World of DTC Marketing
FEBRUARY 28, 2022
Advertising is meant to “sell” your product, but the pharma industry is unique because people don’t just see an ad for a prescription drug and run to their doctor. There is a path between awareness and asking for/receiving an Rx. It’s more than just about understanding; it’s about being relevant to the needs of online health seekers.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Amazon, Teladoc to deliver doctor consultations via Alexa
pharmaphorum
MARCH 2, 2022
Amazon’s encroachment into healthcare advanced a little further this week when the online giant launched a doctor consultation service delivered via its Alexa voice assistant, with the help of telehealth player Teladoc. Users of the service will be able to request non-urgent medical care around the clock, simply by telling Alexa via their Amazon Echo device that they want to speak to a doctor.
Plant-based COVID-19 vaccine approved in Canada
BioPharma Reporter
FEBRUARY 28, 2022
Medicago and GlaxoSmithKline (GSK) have gained approval for Covifenz, the companiesâ plant-based COVID-19 vaccine, from Health Canada.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Intellia presses forward with new results for pioneering CRISPR drug
Bio Pharma Dive
FEBRUARY 28, 2022
The findings build on early evidence that gene editing inside the body could safely and effectively treat disease, and suggest the effects of Intellia's medicine might last.
Doximity study on telehealth flawed
World of DTC Marketing
MARCH 2, 2022
Over 73% of patients plan to continue using telemedicine platforms post-pandemic, according to Doximity’s second edition of its State of Telemedicine Repor t , which was released today. As part of the report, Doximity, the leading digital platform for U.S. medical professionals, analyzed the adoption of telemedicine across its physician user base from January 2020 through June 2021 and conducted a study of patients’ experiences with telemedicine during the same time frame.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Aedesius Health and its lead biopharma company, AO BIO partner with Indegene for a comprehensive commercialization engagement
Pharma Mirror
MARCH 2, 2022
MONTGOMERY, Ala. and PRINCETON, N.J. and LONDON and BANGALORE, India, Aedesius Health, a division of AedesiusOne Ltd, and its biopharmaceutical development incubator AO BIO, which is focused on developing and commercializing neglected and needed therapies, devices, and diagnostics, today announced a comprehensive commercialization partnership with Indegene, a technology-led healthcare solutions provider.
'We have to make a stand': Biotech leaders vow to break ties with Russia over Ukraine war
Bio Pharma Dive
MARCH 1, 2022
Biotech CEOs Paul Hastings and Jeremy Levin explained the goals behind a letter supported by more than 400 executives and investors that calls for drugmakers to stop working with Russian companies.
 The US accounts for more than 40% of all health spending.
World of DTC Marketing
MARCH 1, 2022
The United States accounts for more than 40% of global health spending. Hea Healthcarending made up 5% of total U.S. GDP in 1960. In 020, spending hit almost 20% of total U.S. GDP. It’s a significant issue, but healhealthcare companies are determined to record profits. Americans aren’t using more health care than people in other nations that spend less.
Neglected rare disease patients offered hope in new plan
Pharma Times
FEBRUARY 28, 2022
Unmet need among over 7000 rare diseases is being addressed in a comprehensive action plan
Sterling Pharma Solutions Expands Global API Manufacturing Capabilities with Acquisition of Novartis Facility in Ringaskiddy, Ireland
Pharma Mirror
MARCH 2, 2022
Sterling Pharma Solutions, a global contract development and manufacturing organisation, today announced that it had reached agreement with Novartis to acquire its Ringaskiddy campus (Novartis Ringaskiddy Limited), near Cork, Ireland. Financial details of the sale, which is expected to close in Q4, 2022, have not been disclosed. Under the terms of the agreement, Sterling will acquire the 111-acre site, which includes three active pharmaceutical ingredient (API) manufacturing buildings, as well a
Roche, nearing major trial readouts, starts new Alzheimer's drug study
Bio Pharma Dive
MARCH 3, 2022
As Aduhelm sputters on the market, Roche aims to prove its experimental medicine can work better. A large, multi-year trial is part of that bet.
Is money really more important than people?
World of DTC Marketing
MARCH 4, 2022
Large numbers of people in low-income countries face COVID unprotected, and millions of people would still be alive today if they had had access to a vaccine. Big pharma corporations have been given free rein to prioritize profits ahead of vaccine equality as the richest ten men doubled their fortunes during the pandemic. A new billionaire is being created every 26 hours profiting from vaccines, treatments, tests, etc.
First RSV vaccine trial for infants offers significant results
Pharma Times
MARCH 3, 2022
The phase 3 MELODY study reveals that nirsevimab vaccine reduces lower respiratory tract infections
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
5 Social Security Benefits Facts You Might Not Know
Pharma Mirror
MARCH 2, 2022
While most only really know the basics of Social Security, this administration is an insurance program that provides families and individuals with the necessary information and tools to obtain financial stability. However, claiming Social Security disability benefits can be time-consuming. Moreover, claims are sometimes rejected due to minor errors.
Moderna sued for allegedly infringing patents tied to COVID-19 vaccine
Bio Pharma Dive
FEBRUARY 28, 2022
Arbutus and partner Genevant claim Moderna's coronavirus shot uses delivery technology covered by six patents they hold, an allegation Moderna denies.
More bad research on pharma websites
World of DTC Marketing
MARCH 3, 2022
Press Ganey recently asked1 1,000+ healthcare consumers about their digital behaviors, but unfortunately, their findings mean little to emarketers working within the industry. They are somewhat embarrassing. So let’s look at some of the top insights from the report, along with my snide comments: Consumers turn to pharma sites for reliable information: In the age of empowered consumers, access to reliable healthcare information has never been more demand.
Clinical jobs increase as R&D and lab roles experience record growth
Pharma Times
MARCH 2, 2022
The post-Brexit landscape has witnessed an exponential boom in life science careers
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
UK sets 90% target for electronic patient records in NHS trusts
pharmaphorum
FEBRUARY 28, 2022
UK Health Secretary Sajid Javid has said he wants to accelerate the rollout of electronic patient records (EPR) in the NHS, with 90% of NHS trusts using them by the end of 2023. Javid laid out the new target in a speech to the HSJ Digital Transformation Summit, in which he said that current estimates are that one in five NHS trusts still do not have EPR, and so are missing out on a key technology to deliver better, safer care for patients.
Biogen, struggling to sell Alzheimer's drug, begins layoffs to save money
Bio Pharma Dive
MARCH 3, 2022
Biogen confirmed that some of its U.S. employees have been informed their roles are being eliminated. It's unclear, though, the magnitude of the layoffs or which departments are most affected.
Stevenage Bioscience Catalyst launches accelerator program for biotech start-ups
BioPharma Reporter
MARCH 3, 2022
Stevenage Bioscience Catalyst (SBC) has launched an accelerator program for biotech start-ups focusing on data-enabled drug discovery, genomics and advanced therapies: aiming to give such companies the skills they need to get potential new drugs and therapies to market more quickly.
Previously untreatable lung cancer patients offered new therapy
Pharma Times
MARCH 3, 2022
NICE document recommends Amgen’s Lumykras (sotorasib) to treat non-small-cell lung cancer
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Can psychedelics provide breakthrough in mental health?
pharmaphorum
MARCH 2, 2022
There is a growing pipeline of psychedelic therapies and an expanding body of science to suggest that they may be able to provide an alternative to existing mental health treatments. Ben Hargreaves discovers why medical research in the area has shifted from being highly controversial to being backed by major pharma companies and venture capital. The image of psychedelic drugs within medical research is changing.
Civica targets insulin in effort to produce cheaper drugs
Bio Pharma Dive
MARCH 3, 2022
The nonprofit group announced ambitious plans to begin offering insulin at prices no higher than $30 per vial by early 2024.
Gradual evolution is back: Darwinian theory of gradual process explained in new research
Scienmag
MARCH 2, 2022
Abrupt shifts in the evolution of animals – short periods of time when an organism rapidly changes size or form – have long been a challenge for theorists including Darwin. Now a newly published research paper supports the idea that even these abrupt changes are underpinned by a gradual directional process of successive incremental changes, […].
CHMP recommends Idorsia’s dual acting treatment Quviviq for insomnia patients
Pharma Times
FEBRUARY 28, 2022
Quviviq can be used on a long-term basis, addressing a key limitation of existing therapies
Rare Disease R&D: one step forward, but a long road ahead
pharmaphorum
FEBRUARY 28, 2022
With over 40% of all medicines in the pipeline aimed at rare diseases, the future looks positive for increasing the number of treatments available. However, as Ben Hargreaves discovers, research into the area has only scratched the surface, amid calls for greater funding and greater collaboration to accelerate progress. There are approximately 7,000 different types of rare disease and researchers estimate that there are more than 300 million people worldwide living with such a condition.
Amid biotech downturn, Atlas raises $450M to build new drug startups
Bio Pharma Dive
MARCH 3, 2022
While a stock market slide has made IPOs difficult for young biotech companies, venture capital firms like Atlas are still reloading with new cash to create and invest in new drugmakers.
Which Countries Had the Most Food Industry M&A Deals in 2021?
XTalks
MARCH 3, 2022
In the perfect food industry merger and acquisition (M&A) deal, both parties come out ahead. Last year saw several examples of both buyers and sellers in the food industry walking away with something to position them for more stable, sustainable growth. But which countries had the most food industry M&A deals in 2021? US Leads Food Industry M&A Deals.
Annual obesity costs may soar to £58bn
Pharma Times
MARCH 4, 2022
New detailed datasets will more accurately map out the impact of obesity throughout UK
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Let's personalize your content